Results 41 to 50 of about 1,804,185 (380)
bioRxiv, 2021 The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses ...
Takuya Tada +6 more
semanticscholar +1 more source
SnapShot: Broadly Neutralizing Antibodies
Cell, 2013 Durably elicited by live attenuated virus, less durably by inactivated virusConserved bnAb epitopes:1) Ep1 (res. 380–400) 2) Ep2 (res. 190–200)3) Ep3 (res. 571–579)Despite the extensive variability of measles virus, nAb responses to vaccination are broad becausethe conserved epitopes are immunoprominent.May relate to overlap of the receptor-binding ...
Brian Moldt, Devin Sok, Dennis R. Burton
openaire +3 more sources
Nature Communications, 2017 Eliciting broadly neutralizing antibodies (bnAbs) is a primary HIV vaccine goal, but available immunogens expose epitopes for development of non-nAbs.
Daniel W. Kulp +20 more
doaj +1 more source
Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. [PDF]
, 2017 Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV).
Ashokkumar, Manickam +12 more
core +3 more sources
Scientific Reports, 2021 The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody responses and their association with disease severity.
B. Trinité +25 more
semanticscholar +1 more source
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
Retrovirology, 2018 Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viruses, are a major focus of HIV vaccine design, with data from animal studies confirming their ability to prevent HIV infection.
Elise Landais, Penny L. Moore
doaj +1 more source
Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies [PDF]
, 2012 Lentiviral vectors (LVs) are potent gene transfer vehicles frequently applied in research and recently also in clinical trials. Retargeting LV entry to cell types of interest is a key issue to improve gene transfer safety and efficacy.
Abel, Tobias +5 more
core +3 more sources
Single-domain antibodies and their formatting to combat viral infections [PDF]
, 2018 Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies +4 more
core +2 more sources
Antibody neutralization of HIV-1
Immunology Today, 1996 Neutralizing antibodies are a major component of host defense against viruses, and appear to be particularly important in limiting the spread of cell-free virus. Results from vaccine trials in animal models suggest that these antibodies may contribute to protection against human immunodeficiency virus (HIV) infection.
Poignard, P, Klasse, P, Sattentau, Q
openaire +2 more sources
Kinetic Analysis of Monoclonal Antibody Binding to HIV-1 gp120-derived Hyperglycosylated Cores
Bio-Protocol, 2015 Kinetic analysis of antibodies is one of the important studies for characterization of antibodies and screening of ligands. In our recent study (Ingale et al., 2014), we compared the antigenic profiles and binding characteristics of four HIV-1 envelope ...
Jidnyasa Ingale, Richard Wyatt
doaj +1 more source